Value proposition

Next generation cell therapies for ALK-positive cancer patients

At ALKemist Bio we are developing TCR-T cells that possess the ability to specifically target ALK antigens found on ALK-positive cancer cells, primarily focusing on non-small cell lung cancer patients. By harnessing the power of the immune system and engineering T cells to precisely recognize and combat these cancerous cells, we aim to pave the way for more effective treatments aiming at improving the standard of care.

biotech, immunooncology, oncology, alkpositive, celltherapy, TCR, and ALK